Summit Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0 | $0 | $705,000 | $1.8M |
| Research and development | $537.7M | $150.8M | $59.5M | $52.0M | $85.4M |
| Operating expenses | $1.1B | $226.0M | $609.6M | $87.2M | $109.0M |
| Operating income | — | -$226.0M | -$609.6M | -$72.1M | -$86.2M |
| Interest expense | $0 | $8.7M | $16.5M | $4.4M | $242,000 |
| Pretax income | -$1.1B | -$221.3M | -$614.9M | -$78.8M | -$88.6M |
| Income tax expense | $0 | $0 | $0 | — | $0 |
| Net income | -$1.1B | -$221.3M | -$614.9M | -$78.8M | -$88.6M |
| Balance Sheet | |||||
| Cash and equivalents | $225.3M | $104.9M | $71.4M | $348.6M | $71.8M |
| Current assets | $720.3M | $423.8M | $189.7M | $656.7M | $97.3M |
| Total assets | $751.2M | $435.6M | $202.9M | $664.2M | $113.4M |
| Current liabilities | $73.0M | $41.7M | $20.4M | $38.8M | $25.6M |
| Total liabilities | $92.3M | $46.8M | $125.3M | $537.5M | $30.1M |
| Stockholders' equity | $658.9M | $388.7M | $77.7M | $126.7M | $83.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$322.9M | -$142.1M | -$76.8M | -$41.6M | -$72.6M |
| Depreciation and amortization | $146,000 | $89,000 | $198,000 | $349,000 | $330,000 |
| Stock-based compensation | $732.4M | $51.0M | $14.1M | $11.9M | $12.8M |
| Capital expenditure | $657,000 | $139,000 | $128,000 | $624,000 | $306,000 |
| Free cash flow | -$323.6M | -$142.2M | -$76.9M | -$42.2M | -$72.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 776.2M · Free float 19.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.